How a pill approved 25 years ago transformed cancer treatment

Mel Mann, an Army major based in Detroit, was diagnosed with chronic myeloid leukemia in January 1995 at age 37. Initially given a three-year prognosis, he joined clinical trials for experimental drugs, but none provided lasting relief until he began taking Gleevec in August 1998. By June 1999, he completed a marathon in Anchorage, Alaska, marking a dramatic recovery. The drug’s development began in the 1970s when oncologist Brian Druker proposed targeting the genetic cause of cancer rather than using toxic chemotherapy. Chronic myeloid leukemia was linked to the Philadelphia chromosome, an abnormal enzyme that triggers uncontrolled cell growth. Druker sought a drug to inhibit this enzyme, facing skepticism but securing support from Oregon Health & Science University. Within weeks of moving to Oregon, Druker tested five compounds from what became Novartis, including imatinib (later branded Gleevec). Lab tests showed promise, prompting clinical trials exclusively for patients with chronic myeloid leukemia. Druker advocated aggressively to fast-track the drug, driven by patient desperation and his own conviction. Gleevec was approved by the FDA in 2001, becoming the first targeted cancer therapy. It transformed chronic myeloid leukemia from a fatal disease to a manageable condition, offering patients like Mann decades of survival. The drug’s success marked a turning point in oncology, proving that precision medicine could replace broad-spectrum chemotherapy. Today, Gleevec remains a cornerstone of cancer treatment, with follow-up drugs expanding its applications. Mann’s story and Druker’s research highlight how scientific persistence and targeted therapies can redefine survival outcomes for once-lethal diseases.